United States
Phyteau, Inc., founded in 2017 and headquartered in the United States, addresses the significant global challenge of metabolic diseases through an innovative approach rooted in biotechnology. With its slogan, "Designed by Nature, Delivered by Science," the company focuses on developing a new class of incretin therapy targeting conditions like diabetes, obesity, and NAFLD. These therapies, which trigger essential cellular receptors in the intestines, naturally enhance the levels of metabolic hormones such as GLP-1, PYY, and CCK to regulate blood sugar, appetite, and metabolism.
Phyteau's therapeutics find applications across pharmaceuticals, medical products, and nutraceuticals, with the technology honed over a decade at esteemed institutions like UCLA, Caltech, and Cedars Sinai Medical Center. The startup's innovative prowess is recognized globally, including being a Top 500 Global Deeptech Startup in 2019 by Hello Tomorrow and winning the Leading Innovators in Metabolic Condition Therapeutics award from Global Health & Pharma (GHP) magazine.
Further validating its potential, Phyteau has participated in accelerators like the Plug and Play accelerator in Silicon Valley and RebelBio in Ireland/UK, while receiving seed funding from SOSV and RebelBio in May 2017. Positioned at the intersection of health care and nutrition sectors, Phyteau represents a compelling opportunity for investors aiming to support transformative health solutions.
